Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from LTR Pharma Limited ( (AU:LTP) ) is now available.
LTR Pharma Limited has announced its Annual General Meeting, scheduled for October 24, 2025, in Brisbane. The company is encouraging shareholders to participate in the meeting either in person or by proxy, emphasizing the importance of their votes. This meeting is crucial for stakeholders as it will address resolutions impacting shareholding and company operations, reflecting LTR Pharma’s ongoing strategic efforts to enhance its market presence and product offerings.
More about LTR Pharma Limited
LTR Pharma Limited is a commercial-stage pharmaceutical company focused on delivering innovative therapies for significant unmet medical needs through its proprietary intranasal drug delivery platform. The company has commercialized its rapid-acting treatment technology in Australia and is expanding into the US and other key markets. Its lead products include SPONTAN® and ROXUS®, fast-acting intranasal sprays for erectile dysfunction, and OROFLOW®, under development for Oesophageal Motility Disorders.
Average Trading Volume: 859,406
Technical Sentiment Signal: Strong Buy
For an in-depth examination of LTP stock, go to TipRanks’ Overview page.